Oragenics (OGEN) Other financing activities (2010 - 2023)

Oragenics' (OGEN) quarterly Other financing activities came in at $118.0 in Q4 2023, down 99.99% on a QoQ basis from $1.9 million in Q4 2021.

Oragenics (OGEN) Other financing activities (2010 - 2023) Analysis & Trends

Oragenics (OGEN) has 8 years of Other financing activities data on file, last reported at $118.0 in Q4 2023.

Quarterly Other financing activities changed N/A year-over-year to $118.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$38545.0 (changed N/A YoY) and the FY2024 annual result came in at $6.7 million, up 684.99% from the prior year.
Other financing activities slipped to $118.0 in Q4 2023, from $1.9 million in the prior quarter.
In the past five years, Other financing activities ranged from a high of $5.2 million in Q3 2020 to a low of -$2.0 million in Q2 2021.
A 3-year average of $1.2 million and a median of $997098.5 in 2021 frame the typical range for Other financing activities.
The widest YoY moves for Other financing activities: up 98.14% in 2021, down 98.14% in 2021.
Tracing OGEN's Other financing activities over 3 years: stood at $5.2 million in 2020, then plunged by 63.17% to $1.9 million in 2021, then sank by 99.99% to $118.0 in 2023.
The last three Other financing activities figures came in at $118.0 (Q4 2023), $1.9 million (Q4 2021), and $96000.0 (Q3 2021), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.71 Bn	131.86 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.55 Bn	78.55 Bn	3.93 Bn
3	Argenx Se	65.26 Bn	60.07 Bn	1.37 Bn
4	Moderna	59.81 Bn	54.67 Bn	52.00 Mn
5	BeOne Medicines	42.16 Bn	37.06 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.87 Bn	28.56 Bn	992.69 Mn
7	BioNTech SE	28.13 Bn	9.74 Bn	668.28 Mn
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn
9	Royalty Pharma	27.31 Bn	26.47 Bn	-
10	Oragenics	2.35 Mn	2.35 Mn	-

Download Data